Kempharm, Inc KMPH
We take great care to ensure that the data presented and summarized in this overview for KEMPHARM, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KMPH
View all-
Nantahala Capital Management, LLC New Canaan, CT2.45MShares$12.1 Million0.78% of portfolio
-
Black Rock Inc. New York, NY2.4MShares$11.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.7MShares$8.42 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA1.01MShares$4.99 Million0.05% of portfolio
-
683 Capital Management, LLC New York, NY800KShares$3.95 Million0.34% of portfolio
-
Geode Capital Management, LLC Boston, MA787KShares$3.89 Million0.0% of portfolio
-
State Street Corp Boston, MA683KShares$3.37 Million0.0% of portfolio
-
Janney Montgomery Scott LLC660KShares$3.26 Million0.01% of portfolio
-
Retirement Planning CO Of New England, Inc. Warwick, RI430KShares$2.13 Million1.17% of portfolio
-
Altium Capital Management LP New York, NY341KShares$1.69 Million0.95% of portfolio
Latest Institutional Activity in KMPH
Top Purchases
Top Sells
About KMPH
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Insider Transactions at KMPH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 06
2023
|
R. La Duane Clifton CFO, Secretary & Treasurer |
BUY
Open market or private purchase
|
Direct |
1,000
+6.13%
|
$4,000
$4.96 P/Share
|
Sep 06
2023
|
Thomas Anderson Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$40,000
$4.88 P/Share
|
Sep 05
2023
|
Joshua Schafer CCO & EVP, Bus. Development |
BUY
Open market or private purchase
|
Direct |
500
+12.5%
|
$2,500
$5.13 P/Share
|
Sep 05
2023
|
John B Bode Director |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$50,000
$5.13 P/Share
|
Jun 23
2023
|
Corey Michael Watton Director |
BUY
Open market or private purchase
|
Direct |
275
+21.57%
|
$1,375
$5.95 P/Share
|
Jun 09
2023
|
Corey Michael Watton Director |
BUY
Open market or private purchase
|
Direct |
325
+30.95%
|
$1,625
$5.52 P/Share
|
May 30
2023
|
Corey Michael Watton Director |
BUY
Open market or private purchase
|
Direct |
400
+50.0%
|
$2,000
$5.11 P/Share
|
May 19
2023
|
Joshua Schafer CCO & EVP, Bus. Development |
BUY
Open market or private purchase
|
Direct |
1,000
+25.0%
|
$5,000
$5.42 P/Share
|
May 18
2023
|
John B Bode Director |
BUY
Open market or private purchase
|
Direct |
10,000
+25.36%
|
$50,000
$5.04 P/Share
|
May 18
2023
|
R. La Duane Clifton CFO, Secretary & Treasurer |
BUY
Open market or private purchase
|
Direct |
2,740
+6.17%
|
$10,960
$4.95 P/Share
|
Mar 17
2023
|
Tamara A Seymour Director |
BUY
Open market or private purchase
|
Direct |
519
+41.92%
|
$2,076
$4.82 P/Share
|
Mar 14
2023
|
Joshua Schafer CCO & EVP, Bus. Development |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$8,000
$4.61 P/Share
|
Mar 10
2023
|
R. La Duane Clifton CFO, Secretary & Treasurer |
BUY
Open market or private purchase
|
Direct |
1,725
+13.55%
|
$6,900
$4.15 P/Share
|
Mar 10
2023
|
Timothy J. Sangiovanni SVP, Corporate Controller |
BUY
Open market or private purchase
|
Direct |
1,200
+11.19%
|
$4,800
$4.14 P/Share
|
Mar 09
2023
|
David S Tierney Director |
BUY
Open market or private purchase
|
Direct |
5,000
+31.58%
|
$20,000
$4.15 P/Share
|
Mar 09
2023
|
Matthew R Plooster Director |
BUY
Open market or private purchase
|
Direct |
11,000
+37.29%
|
$44,000
$4.2 P/Share
|
Mar 09
2023
|
Richard W Pascoe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+25.02%
|
$40,000
$4.2 P/Share
|
Jan 13
2023
|
Richard W Pascoe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,500
+32.23%
|
$47,500
$5.44 P/Share
|
Jan 13
2023
|
R. La Duane Clifton CFO, Secretary & Treasurer |
BUY
Open market or private purchase
|
Direct |
635
+3.23%
|
$3,175
$5.7 P/Share
|
Sep 30
2022
|
R. La Duane Clifton CFO, Secretary & Treasurer |
BUY
Open market or private purchase
|
Direct |
1,000
+5.96%
|
$5,000
$5.98 P/Share
|
Last 12 Months Summary
Open market or private purchase | 22.5K shares |
---|